Choices in vaccine trial design in epidemics of emerging infections
- PMID: 30086139
- PMCID: PMC6080746
- DOI: 10.1371/journal.pmed.1002632
Choices in vaccine trial design in epidemics of emerging infections
Abstract
In a Policy Forum, Marc Lipsitch and colleagues discuss trial design issues in infectious disease outbreaks.
Conflict of interest statement
I have read the journal’s policy and the authors of this manuscript have the following competing interests: ML has received consulting fees/honoraria from Pfizer, Merck, Affinivax, and Antigen Discovery and research grants from Pfizer and PATH Vaccine Solutions.
References
-
- WHO. Blueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens. WHO workshop on prioritization of pathogens report. 2015.
-
- National Academy of Sciences Engineering and Medicine. Integrating clinical research into epidemic response: the Ebola experience. National Academies Press; 2017. - PubMed
-
- Cohen J, Kupferschmidt K. Tough choices ahead in Ebola vaccine trials. ScienceMag. 2014; 1–8.
-
- Cohen J. Issues continue to dog the testing of Ebola drugs and vaccines. ScienceMag. 2014.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
